Servier and Cellectis sign $850m cancer collaboration
This article was originally published in Scrip
Servier has signed a strategic collaboration agreement with Cellectis to develop and commercialize up to six cancer products in a deal potentially worth $850m.
You may also be interested in...
Servier SA has moved to broaden its immune-oncology pipeline by signing a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento Therapeutics Inc.'s anti-PD-1 monoclonal antibody (mAb) STI-A1110, adding to its ongoing CAR-T efforts.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.